Tag:
Ascenta Therapeutics
Latest Headlines
Latest Headlines
Sanofi inks $398M cancer R&D deal with Ascenta
Sanofi-Aventis ( NYSE: SNY ) will pay up to $398 million for the rights to several of Ascenta Therapeutics' early-stage oral drug candidates. The French biotech will gain access to MI-773 and
